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Abstract
Background: In patients with Duchenne Muscular Dystrophy (DMD), the absent or diminished dystrophin leads to 
progressive skeletal muscle and heart failure. We evaluated the role of myocardial inflammation as a precipitating 
factor in the development of heart failure in DMD.
Methods: 20 DMD patients (aged 15-18 yrs) and 20 age-matched healthy volunteers were studied and followed-up for 
2 years. Evaluation of myocarditis with cardiovascular magnetic resonance imaging (CMR) was performed using STIR 
T2-weighted (T2W), T1-weighted (T1W) before and after contrast media and late enhanced images (LGE). Left 
ventricular volumes and ejection fraction were also calculated. Myocardial biopsy was performed in patients with 
positive CMR and immunohistologic and polymerase chain reaction (PCR) analysis was employed.
Results: In DMD patients, left ventricular end-diastolic volume (LVEDV) was not different compared to controls. Left 
ventricular end-systolic volume (LVESV) was higher (45.1 ± 6.6 vs. 37.3 ± 3.8 ml, p < 0.001) and left ventricular ejection 
fraction (LVEF) was lower (53.9 ± 2.1 vs. 63 ± 2.4%, p < 0.001). T2 heart/skeletal muscle ratio and early T1 ratio values in 
DMD patients presented no difference compared to controls. LGE areas were identified in six DMD patients. In four of 
them with CMR evidence of myocarditis, myocardial biopsy was performed. Active myocarditis was identified in one 
and healing myocarditis in three using immunohistology. All six patients with CMR evidence of myocarditis had a rapid 
deterioration of left ventricular function during the next year.
Conclusions: DMD patients with myocardial inflammation documented by CMR had a rigorous progression to heart 
failure.
Background
Duchenne Muscular Dystrophy (DMD) is a myopathy
characterized by a defect in the p21 band of the X chro-
mosome that is responsible for dystrophin, a protein
located on the inner surface of the sarcolemma. In
affected individuals, the absent or diminished dystrophin
leads to progressive skeletal muscle and heart failure [1].
Abnormal dystrophin has also been identified as a poten-
tial susceptibility gene for viral infection of the myocar-
dium [2]. Additionally, dystrophin deficiency markedly
potentiates the unfavorable course of enterovirus induced
cardiomyopathy [3].
Cardiovascular magnetic resonance imaging (CMR)
has the unique ability to detect coronary anatomy, func-
tion and viability in one examination [4]. The use of a
combination of STIR T2-weighted (T2W), T1-weighted
(T1W) before and after contrast media and late enhanced
images (LGE) can accurately diagnose the presence of
myocardial inflammation missed by other imaging tech-
niques [5]. T2W images indicate oedema in myocarditis
with a sensitivity of 84% and specificity of 74% [6]. Rela-
tive myocardial enhancement and LGE detect myocardi-
tis with a sensitivity of 80% and a specificity of 68% and a
sensitivity of 44% and a specificity of 100%, respectively
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[6]. Recently, late gadolinium enhanced areas were identi-
fied in DMD patients and their clinical significance is
under evaluation [7,8].
Our aim was to evaluate a population of DMD patients,
suspected for myocarditis, using CMR and myocardial
biopsy, in order to examine the hypothesis that myocar-
dial inflammation could be a precipitating factor for heart
failure in these patients.
Methods
Patient population
In this prospective study, twenty consecutive DMD
patients (aged 15-18 years) selected from Pediatric Neu-
romuscular clinics due to a recent onset (last six months)
of atypical chest discomfort or fatigue without new ECG
changes, were evaluated in our tertiary cardiac center and
followed-up for 2 years. All patients were male and pre-
sented with proximal muscle weakness before age of 5
years, and increased serum creatine kinase. They were
under prophylactic treatment with perindopril since the
age of 10 yrs. The diagnosis of DMD was initially based
on the characteristic clinical history and neuromuscular
findings and was confirmed in all of them by DNA test-
ing. The DMD patients had lost ambulation between 7
and 11 years; they were wheelchair-bound and had mod-
erate to severe scoliosis. All of them had evidence of right
ventricular hypertrophy and non-specific ST changes in
the ECG and in the Holter monitor examination pre-
sented evidence of supraventricular ectopy. Their results
were compared with those of 20 age and sex-matched
healthy volunteers. In DMD patients with CMR positive
for myocardial inflammation, a myocardial biopsy was
also considered, as part of standard evaluation of sus-
pected myocarditis.
All subjects (or their parents) gave informed consent.
The study was approved by the hospital's ethics commit-
tee.
Methodology
A. CMR evaluation of inflammation
Cardiovascular magnetic resonance examination was
performed in a 1.5 T Philips Intera system using STIR
T2-weighted (T2-W), T1-weighted (T1-W) before and
after contrast media injection and late enhanced images
(LGE). ECG-triggered, STIR T2-W multislice spin-echo
sequence was performed in axial orientation and the sig-
nal ratio measured from the region of interest covering
the left ventricular myocardium as well as within a skele-
tal muscle in the same slice. T2-W, an inherent indicator
of tissue water content, is increased in inflammation or
necrosis due to the development of edema, such as dur-
ing myocardial infarction or myocarditis.
ECG-triggered T1-W multislice spin-echo images were
also obtained in axial orientation with identical parame-
ters before and after an intravenous bolus of 0.1 mmol/kg
Gd-DTPA. Measurements after Gd-DTPA were started
within 1 minute of injection (early T1) in the same area as
in T2-W. The extracellular T1-enhancing contrast agent
was used to enhance the detection of pathology on CMR
Gd-DTPA. Higher levels of early myocardial enhance-
ment after gadolinium are most likely due to increased
cell membrane permeability [6]. This process is an impor-
tant contributor because inflammation damages cell
membrane through both T-cell perforin and B-cell anti-
body/complement-mediated mechanisms.
Immediately after the second set of T1-W images, 0.1
mmol/kg Gd-DTPA was given again and epicardial late
gadolinium-enhanced areas (LGE) were taken 15 min
later, using an a 3D-T1-TFE sequence, preconditioned
with a 180 degrees inversion pulse (flip angle = 15°, TE =
1.4 msec, TR = 5.5 ms, TI 225 to 275 ms as individually
optimized to null myocardial signal, matrix 256 × 192 and
slice thickness = 5 mm). Images were analyzed according
to previously described protocols [6]. The exact
pathophysiology of delayed gadolinium enhancement in
myocarditis is still under investigation. Myocardial
necrosis in the acute phase appears to play a major role. A
combined CMR approach using T2-W, early and late gad-
olinium enhancement has a sensitivity of 76%, a specific-
ity of 95.5% and a diagnostic accuracy of 85% [6].
B. CMR functional study
For each subject, localizing scans were obtained to define
the long (2-chamber) axis of the left ventricle. A mid ven-
tricular short axis view was then prescribed, and used to
plan a 4-chamber view. The short axis orientation was
defined accurately, perpendicular to both the 2- and 4-
chamber views. To cover the entire left ventricle, 10 con-
tiguous (gap = 0 mm) short axis slices were acquired in
each study. The imaging sequence was a 2D, multi-phase
(16 cardiac phases were acquired per cardiac cycle result-
ing to a temporal resolution of 47 ms for a heart rate of 80
beats/min), steady-state free-precession (SSFP) sequence
(TE = 1.5 ms, TR = 3.1 ms, flip angle = 70°, slice thickness
= 8 mm, acquired in-plane spatial resolution = 1.8 mm ×
2.0 mm) characterized by the application of balanced gra-
dients in all directions.
C. Endomyocardial Biopsy (EMB)
After written informed consent, 10 endomyocardial spec-
imens (EMBs) were obtained from the right side of the
ventricular septum of each patient with a flexible biop-
tome (Westmed, Germany) via the femoral vein
approach. Four myocardial specimens were used for the
histological evaluation according to the Dallas criteria
and immunohistochemistry respectively, whereas theMavrogeni et al. BMC Neurology 2010, 10:33
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remaining 6 were subjected to DNA and RNA extraction
of viral genomes.
D. Histopathologic analysis
EMBs were stained with hematoxylin-eosin, Masson's
trichrome as well as Giemsa stain and examined by light
microscopy [8]. For immunohistological identification of
cardiac immune cells, tissue sections were treated with an
avidin-biotin-immunoperoxidase method according to
the manufacturer's protocol (Vectastain Elite ABC Kit,
Vector), applying the following monoclonal antibodies:
CD3 (T cells, Novocastra Laboratories) and PGM1 (mac-
rophages, Dako).
The detection of >14 infiltrating leukocytes/mm2 in the
presence of myocyte damage and or fibrosis in addition to
enhanced HLA class II expression in professional anti-
gen-presenting immune cells and endothelium was used
for the diagnosis of active myocarditis. Healing myo-
carditis was considered if the inflammation was less
extensive (<14 leukocytes/mm2), whereas healed myo-
carditis was characterized by multifocal fibrosis or scar-
ring without inflammation (0 to 3 leukocytes/mm2,
which is identical to normal myocardium [9].
Detection of viral genomes
DNA and RNA were extracted simultaneously from fro-
zen heart muscle tissue probes. Polymerase chain reac-
tion (PCR)/reverse transcriptase (RT)-PCR was
performed for the detection of EVs (including Coxsackie-
viruses and Echoviruses), ADVs, Parvovirus B19
(PVB19), Human Cytomegalovirus, Epstein-Barr-virus,
Herpes virus 1-6, Chlamydia pneumoniae and trachoma-
tis. The quality (purity) and quantity of the extracted
nucleic acids (DNA, RNA) was evaluated on a Nanodrop
2000c spectrophotometer (ThermoScientific). As a con-
trol for the successful extraction of RNAs, as well as for
the presence of PCR inhibitors a Reverse Transcription
Real Time PCR assay was designed with primer/probe
sequences from the G-6PDH (glucose-6-phosphate dehy-
drogenase) or b2-microglobulin or human acidic ribo-
somal protein cDNAs (data not shown). For the
verification of the DNA extraction a conventional PCR
assay was designed with specific primers for the human
b-globin gene (IVS-2, data not shown) [10-12].
DNA extraction DNA was extracted with the use of the
DNeasy tissue Kit (QIAGEN, BioAnalytica, Athens,
Greece) according to the manufacturer's instructions and
was stored at -20°C for further processing.
RNA extraction Total RNA was extracted with the use of
RNeasy Mini Kit (QIAGEN, BioAnalytica, Athens,
Greece) according to the manufacturer's instructions.
Total RNA was collected in 40 μl of RNase free water.
E. Statistical analysis
Continuous data were expressed as mean ± SD. Statistical
analysis was performed using Mann-Whitney U-test. A
p-value of < 0.05 was considered for statistical signifi-
cance.
Results
In DMD patients, left ventricular end-diastolic volume
(LVEDV) was not different compared to controls (96.9 ±
12.9 vs. 101 ± 13.2 ml, p:NS). However, left ventricular
end-systolic volume (LVESV) was higher (45.1 ± 6.6 vs.
37.3 ± 3.8 ml, p < 0.001) and left ventricular ejection frac-
tion (LVEF) was lower compared to controls (53.9 ± 2.1
vs. 63 ± 2.4%, p < 0.001). T2 heart/skeletal muscle ratio
and early T1 ratio values in DMD patients did not differ
compared to controls (1.33 ± 0.23 vs 1.32 ± 0.14 and 3.62
± 1.47 vs 3.60 ± 0.08, p:NS, respectively).
However, in one patient, although left ventricular
indexes were within normal range, the T2 ratio and early
T1 values were increased compared to controls (2.3 and
12 respectively) and a intramural late gadolinium
enhanced area (LGE) in the intraventricular septum of
the left ventricle was also identified (Figure 1). Epicardial
LGE areas in inferolateral wall of left ventricle were also
identified in other five DMD patients, although T2 ratio
and early T1 were normal (Figure 2).
In four out of six DMD patients with LGE areas, myo-
cardial biopsy was performed. Evidence of active myo-
carditis was present in histological analysis in the patient
w i t h  a b n o r m a l  T 2  r a t i o ,  e a r l y  T 1  a n d  p o s i t i v e  L G E
(detection of >14 infiltrating leukocytes/mm2 in the pres-
ence of myocyte damage and or fibrosis) (Figure 3), while
evidence of healing myocarditis (<14 leukocytes/mm2),
Figure 1 Intramural late gadolinium enhanced area (LGE) in the 
intraventricular septum (arrows), indicative of active myocardial 
inflammation.Mavrogeni et al. BMC Neurology 2010, 10:33
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was identified in the other three with positive LGE (Fig-
ure 4). LGE areas were not identified in any of the con-
trols.
Polymerase chain reaction (PCR) revealed Human
Cytomegalovirus (CMV) in the patient with active myo-
carditis, while Parvovirus B19 and Coxsackie B virus were
identified in the remaining three patients with postero-
lateral LGE areas. During the next year and in a time
period between 6-12 months, all 6 DMD patients with
CMR evidence of myocarditis (LGE+) developed left ven-
tricular dilatation, rapid deterioration of left ventricular
ejection fraction and arrhythmias including bigeminy
and/or ventricular tachycardia. In the second year of fol-
low-up, two of them died due to ventricular tachycardia
and the other 4 were in end-stage heart failure. It is also
important to mention that the DMD patients without evi-
dence of myocarditis (LGE-) remained stable and did not
develop any deterioration of heart function during the
next 2 years. A Kaplan-Meier graph of the probability of
heart failure between LGE+ and LGE- DMD patients is
presented in figure 5.
Discussion
In this study, the evaluation of twenty DMD patients by
CMR revealed the presence of myocardial fibrosis in 6/
20. DMD patients suspected for myocarditis were oligo-
symptomatic and their left ventricular indexes, although
within normal range, presented significantly lower than
those of age - matched controls. In DMD subjects with
positive CMR findings, endomyocardial biopsy assessed
the presence of active and healing myocarditis and PCR
Figure 2 Epicardial late gadolinium enhanced area (LGE) in the 
inferior LV wall (arrows), indicative of healing myocarditis.
Figure 3 Pathology image (arrows), indicative of active myocar-
dial inflammation (hematoxylin-eosin, ×200), corresponding to 
figure 1.
Figure 4 Pathology image (arrows), indicative of healing myo-
carditis (hematoxylin-eosin, ×200), corresponding to figure 2.
Figure 5 A Kaplan-Meier graph of the probability of heart failure 
between LGE+ (continuous line) and LGE- (dotted line) DMD pa-
tients.Mavrogeni et al. BMC Neurology 2010, 10:33
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evaluation documented the presence of CMV, Coxsackie
and Parvo-B19 in some of them. During the next 1- 2
years, DMD patients with evidence of myocardial inflam-
mation had a rapid progression to heart failure and death,
in contrast to the DMD patients without evidence of
myocarditis by CMR, who remained stable.
This is an initial report documenting the presence of
myocarditis in a population of oligo-symptomatic DMD
patients, using CMR and verified by myocardial biopsy.
Our group has already described a case of a DMD patient
with sudden clinical deterioration and clinical suspicion
of myocarditis (this patient is not included in the present
study), initially diagnosed by CMR and then verified by
myocardial biopsy [13]. CMR has been previously used as
a non-invasive index on tissue structure. In patients with
DMD, quantitative maps of relaxation times of peripheral
muscles and myocardium were closely related to muscu-
lar function and could be used to evaluate the response to
treatment [1,14-17].
The cardiac involvement in DMD, which is character-
ized by cardiac muscle degeneration with fibrous tissue
replacement and fatty infiltration, typically occurs late in
the course of the disease. It is estimated that about 75% of
DMD patients die due to respiratory failure and about
20% of them due to heart failure [18]. These findings
could be the result of chronic immobilization [1] or long-
standing degenerative process due to the lack or abnor-
mal dystrophin [7,8]. However, in a small percentage of
patients, myocardial impairment may progress more
quickly than skeletal muscle impairment and lead to sud-
den heart failure and death in relatively short period of
time [18,19].
In an effort to detect early myocardial disease, previous
studies used different non-invasive techniques, including
201-Thallium scintigraphy [20] and echocardiography
[21]. In a group of DMD patients studied by Corrado et al
[22], decreased LV ejection fraction (LVEF), could pro-
vide some prognostic value regarding mortality but
lacked prognostic ability in a period of five years follow-
up. Giglio et al [23] also found that ultrasound tissue
characterization can detect preclinical myocardial struc-
tural changes in DMD children. Recently, myocardial
scintigraphy identified that severe transmural fibrosis and
fatty infiltration were common in segments with perfu-
sion defects [24]. Additionally, echocardiography
assessed areas of increased echo amplitude in the poste-
rior wall of LV, suspected to be sites of myocardial fibrosis
[25]. CMR due to its unique ability to detect function,
inflammation and viability in one examination [26] is an
excellent diagnostic tool to evaluate the pathophysiology
of early myocardial involvement in DMD patients.
Our findings were in agreement with previous studies,
which also assessed the presence of epicardial myocardial
fibrosis in DMD patients using CMR [6,7] and other non-
invasive imaging techniques [24,25]. Furthermore, by
performing endo-myocardial biopsy, we documented the
presence of histological changes and of viral genomes,
which can contribute to myocarditis and precipitate heart
failure. Sampling error is a significant limitation to the
diagnostic accuracy of the endomyocardial biopsy.
Although 4-6 biopsy samples are routinely performed
during a diagnostic procedure, a careful post-mortem
analysis of proven myocarditis cases demonstrated that >
17 samples were necessary to correctly diagnose myo-
carditis in >80% of cases [27]. To eliminate the sampling
error, we took 10 biopsy samples. Furthermore, it has
been well documented that the incidence of myocarditis
diagnosed by standard hematoxylin-eosin criteria is
underestimated and the Dallas criteria yield diagnostic
information in only 10-20% of cases [28]. Growing evi-
dence exists, that the detection of viral genomes by PCR
identifies a group of patients with a poorer prognosis,
who may benefit from interferon-b therapy [9]. The
superimposition of myocarditis on a chronic myocardial
disease has been previously commented upon. Kremasti-
nos et al documented the presence of myocarditis in thal-
assemic patients [29]. Moreover, evidence of myocarditis
was also documented in patients with arrythmogenic
right ventricle [30]. It is possible that patients with com-
promised left ventricular structure are more sensitive to
viral challenges. However, the detection of these viral
genomes in the biopsy supports but does not necessarily
prove causation.
Although it is known that the absence or decrease of
dystrophin leads to progressive skeletal muscle and heart
failure [1], recently has been also documented that abnor-
mal dystrophin can act as a potential susceptibility gene
for viral infection of the myocardium [2] and as a factor
that markedly increases enterovirus induced cardiomyo-
pathy [3]. The rapid LV deterioration of all our DMD
patients with CMR evidence of myocarditis (LGE+) dur-
ing the next 2 years and the findings of myocardial
inflammation and viral genomes in the myocardium fur-
ther support the hypothesis that myocarditis can act as a
precipitating factor for the development of heart failure
in DMD patients.
Limitations of the study
The small number of examined patients and the small
number of myocardial biopsies taken from intraventricu-
lar septum and not from the gadolinium late enhanced
areas are the major limitations of this study. Additionally,
our patients were selected due to recent onset of possible
cardiac involvement from Pediatric Neuromuscular Hos-
pitals and do not reflect the real incidence of myocarditis
in the DMD population.Mavrogeni et al. BMC Neurology 2010, 10:33
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Conlusions
In conclusion, in DMD, which is traditionally considered
as a degenerative muscular disease, the myocardial
inflammation documented by CMR and myocardial
biopsy was a precipitating factor for heart failure. DMD
patients with myocarditis had rapid LV deterioration in
contrary to those without, who remained stable during
the 2 years of follow-up. However, further studies are
needed to evaluate the true incidence of myocarditis and
the importance of these findings in the pathophysiology
of development of heart failure in DMD patients.
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